Programs & Pipeline

Infectious diseases represent a continually growing scourge that impacts social and economic development worldwide. Our core focus is on the treatment of HCV (Hepatitis C virus) and HIV infections, which together affect approximately 250 million people worldwide and over 5 million people in the U.S. alone. Existing drugs for each of these indications are ineffective in clearing the virus and have significant side effects; despite the drawbacks, the acute medical need drives global annual sales of over $10B.

As the rate of chronic viral infections continues to rise dramatically and costs associated with care increase, novel treatment options are urgently needed to curb the rise in infection rates.

Presidio Pharmaceuticals was founded in 2006 to rapidly address the continuing need for innovative antiviral therapies. Presidio employs a strategy that uses both novel and validated targets to address the need for new therapies and is pursing a fast pace to push its HCV and HIV programs toward commercialization.

HCV Program >>